ArticlebioRxiv : the preprint server for biology2026
A surviving beta cell subpopulation enriched in patients with T1D.
Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Type 1 diabetes (T1D) is characterized by the autoimmune destruction of pancreatic beta cells. While most beta cells are lost, a subset of beta cells persists years and even decades after disease onset. Studying these surviving cells is challenging, and thus how they escape immune killing remains poorly understood. Here, we applied a gene regulatory network inference-based clustering approach on existing islet scRNAseq data from cadaveric donors with T1D, autoantibody positive donors at risk for T1D, and non-diabetic donors to analyze beta cells from patients with established T1D. This approach identified a novel beta cell subtype enriched in T1D donors defined by the activity of several transcription factors which have well-characterized roles in beta cell survival, most notably IRF1. We found increased expression of immunomodulatory genes (e.g.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.